BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 1450046)

  • 1. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Chandrasekharan C
    Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Small Bowel Neuroendocrine Tumors.
    Larouche V; Akirov A; Alshehri S; Ezzat S
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
    Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
    Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.
    Cidon EU
    World J Gastrointest Oncol; 2017 Jan; 9(1):4-20. PubMed ID: 28144395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The type I interferon system in the etiopathogenesis of autoimmune diseases.
    Rönnblom L
    Ups J Med Sci; 2011 Nov; 116(4):227-37. PubMed ID: 22066971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
    Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
    World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of gastroenteropancreatic neuroendocrine tumors.
    Plöckinger U; Wiedenmann B
    Virchows Arch; 2007 Aug; 451 Suppl 1():S71-80. PubMed ID: 17684765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
    Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X
    Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
    Oberg K; Eriksson B; Janson ET
    Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases].
    Votte A; Iglicki F; Sévenet F; Tabah I; Dupas JL
    Presse Med; 1996 Jan; 25(2):63-7. PubMed ID: 8745720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial.
    Janson ET; Rönnblom L; Ahlström H; Grandér D; Alm G; Einhorn S; Oberg K
    Ann Oncol; 1992 Sep; 3(8):635-8. PubMed ID: 1450046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
    Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
    Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.